Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma
A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KRAS-mutant Metastatic Colorectal Carcinoma
Status: Enrolling
Updated:  3/7/2016
Clinical Research Facility
mi
from
Ocala, FL
Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma
A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KRAS-mutant Metastatic Colorectal Carcinoma
Status: Enrolling
Updated: 3/7/2016
Clinical Research Facility
mi
from
Ocala, FL
Click here to add this to my saved trials
Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma
A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KRAS-mutant Metastatic Colorectal Carcinoma
Status: Enrolling
Updated:  3/7/2016
Clinical Research Facility
mi
from
Port Saint Lucie, FL
Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma
A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KRAS-mutant Metastatic Colorectal Carcinoma
Status: Enrolling
Updated: 3/7/2016
Clinical Research Facility
mi
from
Port Saint Lucie, FL
Click here to add this to my saved trials
Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma
A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KRAS-mutant Metastatic Colorectal Carcinoma
Status: Enrolling
Updated:  3/7/2016
Clinical Research Facility
mi
from
Atlanta, GA
Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma
A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KRAS-mutant Metastatic Colorectal Carcinoma
Status: Enrolling
Updated: 3/7/2016
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma
A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KRAS-mutant Metastatic Colorectal Carcinoma
Status: Enrolling
Updated:  3/7/2016
Clinical Research Facility
mi
from
Chicago, IL
Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma
A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KRAS-mutant Metastatic Colorectal Carcinoma
Status: Enrolling
Updated: 3/7/2016
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma
A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KRAS-mutant Metastatic Colorectal Carcinoma
Status: Enrolling
Updated:  3/7/2016
Clinical Research Facility
mi
from
Joliet, IL
Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma
A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KRAS-mutant Metastatic Colorectal Carcinoma
Status: Enrolling
Updated: 3/7/2016
Clinical Research Facility
mi
from
Joliet, IL
Click here to add this to my saved trials
Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma
A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KRAS-mutant Metastatic Colorectal Carcinoma
Status: Enrolling
Updated:  3/7/2016
Clinical Research Facility
mi
from
Fishers, IN
Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma
A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KRAS-mutant Metastatic Colorectal Carcinoma
Status: Enrolling
Updated: 3/7/2016
Clinical Research Facility
mi
from
Fishers, IN
Click here to add this to my saved trials
Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma
A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KRAS-mutant Metastatic Colorectal Carcinoma
Status: Enrolling
Updated:  3/7/2016
Clinical Research Facility
mi
from
Wichita, KA
Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma
A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KRAS-mutant Metastatic Colorectal Carcinoma
Status: Enrolling
Updated: 3/7/2016
Clinical Research Facility
mi
from
Wichita, KA
Click here to add this to my saved trials
Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma
A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KRAS-mutant Metastatic Colorectal Carcinoma
Status: Enrolling
Updated:  3/7/2016
Clinical Research Facility
mi
from
Paducah, KY
Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma
A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KRAS-mutant Metastatic Colorectal Carcinoma
Status: Enrolling
Updated: 3/7/2016
Clinical Research Facility
mi
from
Paducah, KY
Click here to add this to my saved trials
Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma
A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KRAS-mutant Metastatic Colorectal Carcinoma
Status: Enrolling
Updated:  3/7/2016
Clinical Research Facility
mi
from
Worcester, MA
Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma
A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KRAS-mutant Metastatic Colorectal Carcinoma
Status: Enrolling
Updated: 3/7/2016
Clinical Research Facility
mi
from
Worcester, MA
Click here to add this to my saved trials
Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma
A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KRAS-mutant Metastatic Colorectal Carcinoma
Status: Enrolling
Updated:  3/7/2016
Clinical Research Facility
mi
from
Lebanon, NH
Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma
A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KRAS-mutant Metastatic Colorectal Carcinoma
Status: Enrolling
Updated: 3/7/2016
Clinical Research Facility
mi
from
Lebanon, NH
Click here to add this to my saved trials
Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma
A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KRAS-mutant Metastatic Colorectal Carcinoma
Status: Enrolling
Updated:  3/7/2016
Clinical Research Facility
mi
from
Hudson, NY
Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma
A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KRAS-mutant Metastatic Colorectal Carcinoma
Status: Enrolling
Updated: 3/7/2016
Clinical Research Facility
mi
from
Hudson, NY
Click here to add this to my saved trials
Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma
A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KRAS-mutant Metastatic Colorectal Carcinoma
Status: Enrolling
Updated:  3/7/2016
Clinical Research Facility
mi
from
New York, NY
Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma
A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KRAS-mutant Metastatic Colorectal Carcinoma
Status: Enrolling
Updated: 3/7/2016
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma
A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KRAS-mutant Metastatic Colorectal Carcinoma
Status: Enrolling
Updated:  3/7/2016
Clinical Research Facility
mi
from
High Point, NC
Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma
A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KRAS-mutant Metastatic Colorectal Carcinoma
Status: Enrolling
Updated: 3/7/2016
Clinical Research Facility
mi
from
High Point, NC
Click here to add this to my saved trials
Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma
A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KRAS-mutant Metastatic Colorectal Carcinoma
Status: Enrolling
Updated:  3/7/2016
Clinical Research Facility
mi
from
Columbus, OH
Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma
A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KRAS-mutant Metastatic Colorectal Carcinoma
Status: Enrolling
Updated: 3/7/2016
Clinical Research Facility
mi
from
Columbus, OH
Click here to add this to my saved trials
Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma
A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KRAS-mutant Metastatic Colorectal Carcinoma
Status: Enrolling
Updated:  3/7/2016
Clinical Research Facility
mi
from
Philadelphia, PA
Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma
A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KRAS-mutant Metastatic Colorectal Carcinoma
Status: Enrolling
Updated: 3/7/2016
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma
A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KRAS-mutant Metastatic Colorectal Carcinoma
Status: Enrolling
Updated:  3/7/2016
Clinical Research Facility
mi
from
Amarillo, TX
Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma
A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KRAS-mutant Metastatic Colorectal Carcinoma
Status: Enrolling
Updated: 3/7/2016
Clinical Research Facility
mi
from
Amarillo, TX
Click here to add this to my saved trials
Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma
A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KRAS-mutant Metastatic Colorectal Carcinoma
Status: Enrolling
Updated:  3/7/2016
Clinical Research Facility
mi
from
Austin, TX
Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma
A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KRAS-mutant Metastatic Colorectal Carcinoma
Status: Enrolling
Updated: 3/7/2016
Clinical Research Facility
mi
from
Austin, TX
Click here to add this to my saved trials
Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma
A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KRAS-mutant Metastatic Colorectal Carcinoma
Status: Enrolling
Updated:  3/7/2016
Clinical Research Facility
mi
from
Dallas, TX
Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma
A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KRAS-mutant Metastatic Colorectal Carcinoma
Status: Enrolling
Updated: 3/7/2016
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma
A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KRAS-mutant Metastatic Colorectal Carcinoma
Status: Enrolling
Updated:  3/7/2016
Clinical Research Facility
mi
from
Temple, TX
Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma
A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KRAS-mutant Metastatic Colorectal Carcinoma
Status: Enrolling
Updated: 3/7/2016
Clinical Research Facility
mi
from
Temple, TX
Click here to add this to my saved trials
Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma
A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KRAS-mutant Metastatic Colorectal Carcinoma
Status: Enrolling
Updated:  3/7/2016
Clinical Research Facility
mi
from
Tyler, TX
Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma
A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KRAS-mutant Metastatic Colorectal Carcinoma
Status: Enrolling
Updated: 3/7/2016
Clinical Research Facility
mi
from
Tyler, TX
Click here to add this to my saved trials
Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma
A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KRAS-mutant Metastatic Colorectal Carcinoma
Status: Enrolling
Updated:  3/7/2016
Clinical Research Facility
mi
from
Roanoke, VA
Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma
A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KRAS-mutant Metastatic Colorectal Carcinoma
Status: Enrolling
Updated: 3/7/2016
Clinical Research Facility
mi
from
Roanoke, VA
Click here to add this to my saved trials
Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma
A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KRAS-mutant Metastatic Colorectal Carcinoma
Status: Enrolling
Updated:  3/7/2016
Research Site
mi
from
Bordeaux Cedex,
Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma
A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KRAS-mutant Metastatic Colorectal Carcinoma
Status: Enrolling
Updated: 3/7/2016
Research Site
mi
from
Bordeaux Cedex,
Click here to add this to my saved trials
Identification of Biomarkers for Early Detection of Pancreatic Cancer
Michigan Center for Pancreatic Cancer Molecular Diagnosis: The Serum Protein Microarray Project
Status: Enrolling
Updated:  3/7/2016
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Identification of Biomarkers for Early Detection of Pancreatic Cancer
Michigan Center for Pancreatic Cancer Molecular Diagnosis: The Serum Protein Microarray Project
Status: Enrolling
Updated: 3/7/2016
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Study of Blood Samples From Older Patients at High Risk of Developing Prostate Cancer and From Healthy Male Participants
Antioxidant Enzymes and Oxidative DNA Damage in Subjects With 'High-Risk' for Prostate Cancer
Status: Enrolling
Updated:  3/8/2016
University Suburban Health Center
mi
from
Cleveland, OH
Study of Blood Samples From Older Patients at High Risk of Developing Prostate Cancer and From Healthy Male Participants
Antioxidant Enzymes and Oxidative DNA Damage in Subjects With 'High-Risk' for Prostate Cancer
Status: Enrolling
Updated: 3/8/2016
University Suburban Health Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study of Blood Samples From Older Patients at High Risk of Developing Prostate Cancer and From Healthy Male Participants
Antioxidant Enzymes and Oxidative DNA Damage in Subjects With 'High-Risk' for Prostate Cancer
Status: Enrolling
Updated:  3/8/2016
University Hospitals Seidman Cancer Center
mi
from
Cleveland, OH
Study of Blood Samples From Older Patients at High Risk of Developing Prostate Cancer and From Healthy Male Participants
Antioxidant Enzymes and Oxidative DNA Damage in Subjects With 'High-Risk' for Prostate Cancer
Status: Enrolling
Updated: 3/8/2016
University Hospitals Seidman Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study of Blood Samples From Older Patients at High Risk of Developing Prostate Cancer and From Healthy Male Participants
Antioxidant Enzymes and Oxidative DNA Damage in Subjects With 'High-Risk' for Prostate Cancer
Status: Enrolling
Updated:  3/8/2016
UHHS Chagrin Highlands Medical Center
mi
from
Cleveland, OH
Study of Blood Samples From Older Patients at High Risk of Developing Prostate Cancer and From Healthy Male Participants
Antioxidant Enzymes and Oxidative DNA Damage in Subjects With 'High-Risk' for Prostate Cancer
Status: Enrolling
Updated: 3/8/2016
UHHS Chagrin Highlands Medical Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma
A Phase II Study of Bendamustine (B), Etoposide (E), Dexamethasone (D), and GCSF for Peripheral Blood Hematopoietic Stem Cell Mobilization (BED)
Status: Enrolling
Updated:  3/8/2016
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma
A Phase II Study of Bendamustine (B), Etoposide (E), Dexamethasone (D), and GCSF for Peripheral Blood Hematopoietic Stem Cell Mobilization (BED)
Status: Enrolling
Updated: 3/8/2016
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Using FDG-PET During Radiation Therapy in Non-Small Cell Lung Cancer
Using FDG-PET Acquired During the Course of Radiation Therapy to Individualize Adaptive Radiation Dose Escalation in Patients With Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/8/2016
University of Michigan Cancer Center
mi
from
Ann Arbor, MI
Using FDG-PET During Radiation Therapy in Non-Small Cell Lung Cancer
Using FDG-PET Acquired During the Course of Radiation Therapy to Individualize Adaptive Radiation Dose Escalation in Patients With Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/8/2016
University of Michigan Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Phase II Trial Evaluating Axitinib In Patients With Unresectable, Recurrent Or Metastatic Head And Neck Cancer
Phase II Trial Evaluating Axitinib (AG-013736) In Patients With Unresectable, Recurrent Or Metastatic Head And Neck Cancer
Status: Enrolling
Updated:  3/8/2016
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Phase II Trial Evaluating Axitinib In Patients With Unresectable, Recurrent Or Metastatic Head And Neck Cancer
Phase II Trial Evaluating Axitinib (AG-013736) In Patients With Unresectable, Recurrent Or Metastatic Head And Neck Cancer
Status: Enrolling
Updated: 3/8/2016
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma
Phase II Study of the PARP Inhibitor, Olaparib, in Adult Patients With Recurrent/Metastatic Ewing's Sarcoma Following Failure of Prior Chemotherapy
Status: Enrolling
Updated:  3/8/2016
Massachusetts General Hospital
mi
from
Boston, MA
Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma
Phase II Study of the PARP Inhibitor, Olaparib, in Adult Patients With Recurrent/Metastatic Ewing's Sarcoma Following Failure of Prior Chemotherapy
Status: Enrolling
Updated: 3/8/2016
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma
Phase II Study of the PARP Inhibitor, Olaparib, in Adult Patients With Recurrent/Metastatic Ewing's Sarcoma Following Failure of Prior Chemotherapy
Status: Enrolling
Updated:  3/8/2016
Brigham and Women's Hosp
mi
from
Boston, MA
Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma
Phase II Study of the PARP Inhibitor, Olaparib, in Adult Patients With Recurrent/Metastatic Ewing's Sarcoma Following Failure of Prior Chemotherapy
Status: Enrolling
Updated: 3/8/2016
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma
Phase II Study of the PARP Inhibitor, Olaparib, in Adult Patients With Recurrent/Metastatic Ewing's Sarcoma Following Failure of Prior Chemotherapy
Status: Enrolling
Updated:  3/8/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma
Phase II Study of the PARP Inhibitor, Olaparib, in Adult Patients With Recurrent/Metastatic Ewing's Sarcoma Following Failure of Prior Chemotherapy
Status: Enrolling
Updated: 3/8/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Treating Cancer-Related Fatigue Through Systematic Light Exposure
Treating Cancer-Related Fatigue Through Systematic Light Exposure
Status: Enrolling
Updated:  3/8/2016
Hackensack University Medical Center
mi
from
Hackensack, NJ
Treating Cancer-Related Fatigue Through Systematic Light Exposure
Treating Cancer-Related Fatigue Through Systematic Light Exposure
Status: Enrolling
Updated: 3/8/2016
Hackensack University Medical Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Treating Cancer-Related Fatigue Through Systematic Light Exposure
Treating Cancer-Related Fatigue Through Systematic Light Exposure
Status: Enrolling
Updated:  3/8/2016
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Treating Cancer-Related Fatigue Through Systematic Light Exposure
Treating Cancer-Related Fatigue Through Systematic Light Exposure
Status: Enrolling
Updated: 3/8/2016
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Click here to add this to my saved trials
Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children
Enhancing Connections Telephone Program: A Cancer Education Program for Parents
Status: Enrolling
Updated:  3/8/2016
Bozeman Deaconess Hospital
mi
from
Bozeman, MT
Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children
Enhancing Connections Telephone Program: A Cancer Education Program for Parents
Status: Enrolling
Updated: 3/8/2016
Bozeman Deaconess Hospital
mi
from
Bozeman, MT
Click here to add this to my saved trials
Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children
Enhancing Connections Telephone Program: A Cancer Education Program for Parents
Status: Enrolling
Updated:  3/8/2016
Kadlec Hematology & Oncology
mi
from
Kennewick, WA
Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children
Enhancing Connections Telephone Program: A Cancer Education Program for Parents
Status: Enrolling
Updated: 3/8/2016
Kadlec Hematology & Oncology
mi
from
Kennewick, WA
Click here to add this to my saved trials
Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children
Enhancing Connections Telephone Program: A Cancer Education Program for Parents
Status: Enrolling
Updated:  3/8/2016
Tri-Cities Cancer Center
mi
from
Kennewick, WA
Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children
Enhancing Connections Telephone Program: A Cancer Education Program for Parents
Status: Enrolling
Updated: 3/8/2016
Tri-Cities Cancer Center
mi
from
Kennewick, WA
Click here to add this to my saved trials
Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children
Enhancing Connections Telephone Program: A Cancer Education Program for Parents
Status: Enrolling
Updated:  3/8/2016
SCCA at EvergreenHealth
mi
from
Kirkland, WA
Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children
Enhancing Connections Telephone Program: A Cancer Education Program for Parents
Status: Enrolling
Updated: 3/8/2016
SCCA at EvergreenHealth
mi
from
Kirkland, WA
Click here to add this to my saved trials
Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children
Enhancing Connections Telephone Program: A Cancer Education Program for Parents
Status: Enrolling
Updated:  3/8/2016
Skagit Valley Hospital
mi
from
Mount Vernon, WA
Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children
Enhancing Connections Telephone Program: A Cancer Education Program for Parents
Status: Enrolling
Updated: 3/8/2016
Skagit Valley Hospital
mi
from
Mount Vernon, WA
Click here to add this to my saved trials
Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children
Enhancing Connections Telephone Program: A Cancer Education Program for Parents
Status: Enrolling
Updated:  3/8/2016
Olympic Medical Center
mi
from
Port Angeles, WA
Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children
Enhancing Connections Telephone Program: A Cancer Education Program for Parents
Status: Enrolling
Updated: 3/8/2016
Olympic Medical Center
mi
from
Port Angeles, WA
Click here to add this to my saved trials
Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children
Enhancing Connections Telephone Program: A Cancer Education Program for Parents
Status: Enrolling
Updated:  3/8/2016
Group Health Cooperative
mi
from
Redmond, WA
Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children
Enhancing Connections Telephone Program: A Cancer Education Program for Parents
Status: Enrolling
Updated: 3/8/2016
Group Health Cooperative
mi
from
Redmond, WA
Click here to add this to my saved trials
Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children
Enhancing Connections Telephone Program: A Cancer Education Program for Parents
Status: Enrolling
Updated:  3/8/2016
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children
Enhancing Connections Telephone Program: A Cancer Education Program for Parents
Status: Enrolling
Updated: 3/8/2016
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children
Enhancing Connections Telephone Program: A Cancer Education Program for Parents
Status: Enrolling
Updated:  3/8/2016
Swedish Cancer Institute
mi
from
Seattle, WA
Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children
Enhancing Connections Telephone Program: A Cancer Education Program for Parents
Status: Enrolling
Updated: 3/8/2016
Swedish Cancer Institute
mi
from
Seattle, WA
Click here to add this to my saved trials
Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children
Enhancing Connections Telephone Program: A Cancer Education Program for Parents
Status: Enrolling
Updated:  3/8/2016
MultiCare Tacoma General Hospital
mi
from
Tacoma, WA
Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children
Enhancing Connections Telephone Program: A Cancer Education Program for Parents
Status: Enrolling
Updated: 3/8/2016
MultiCare Tacoma General Hospital
mi
from
Tacoma, WA
Click here to add this to my saved trials
Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children
Enhancing Connections Telephone Program: A Cancer Education Program for Parents
Status: Enrolling
Updated:  3/8/2016
Wenatchee Valley Medical Center
mi
from
Wenatchee, WA
Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children
Enhancing Connections Telephone Program: A Cancer Education Program for Parents
Status: Enrolling
Updated: 3/8/2016
Wenatchee Valley Medical Center
mi
from
Wenatchee, WA
Click here to add this to my saved trials
Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer
An Open-Label, Randomized, Phase II/III Trial of Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer
Status: Enrolling
Updated:  3/8/2016
Peregrine Pharmaceuticals Investigational Site
mi
from
Bakersfield, CA
Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer
An Open-Label, Randomized, Phase II/III Trial of Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 3/8/2016
Peregrine Pharmaceuticals Investigational Site
mi
from
Bakersfield, CA
Click here to add this to my saved trials
Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer
An Open-Label, Randomized, Phase II/III Trial of Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer
Status: Enrolling
Updated:  3/8/2016
Peregrine Pharmaceuticals Investigational Site
mi
from
Tinley Park, IL
Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer
An Open-Label, Randomized, Phase II/III Trial of Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 3/8/2016
Peregrine Pharmaceuticals Investigational Site
mi
from
Tinley Park, IL
Click here to add this to my saved trials
Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors
Phase III, Double-Blind, Placebo-Controlled, Crossover Study Evaluating Aprepitant in Combination With a 5HT3 & Dexamethasone in Patients With Germ Cell Tumors Undergoing 5 Day Cisplatin-Based Chemotherapy Regimen
Status: Enrolling
Updated:  3/8/2016
Indiana University Simon Cancer Center
mi
from
Indianapolis, IN
Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors
Phase III, Double-Blind, Placebo-Controlled, Crossover Study Evaluating Aprepitant in Combination With a 5HT3 & Dexamethasone in Patients With Germ Cell Tumors Undergoing 5 Day Cisplatin-Based Chemotherapy Regimen
Status: Enrolling
Updated: 3/8/2016
Indiana University Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors
Phase III, Double-Blind, Placebo-Controlled, Crossover Study Evaluating Aprepitant in Combination With a 5HT3 & Dexamethasone in Patients With Germ Cell Tumors Undergoing 5 Day Cisplatin-Based Chemotherapy Regimen
Status: Enrolling
Updated:  3/8/2016
Medical Consultants, P.C.
mi
from
Muncie, IN
Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors
Phase III, Double-Blind, Placebo-Controlled, Crossover Study Evaluating Aprepitant in Combination With a 5HT3 & Dexamethasone in Patients With Germ Cell Tumors Undergoing 5 Day Cisplatin-Based Chemotherapy Regimen
Status: Enrolling
Updated: 3/8/2016
Medical Consultants, P.C.
mi
from
Muncie, IN
Click here to add this to my saved trials
Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors
Phase III, Double-Blind, Placebo-Controlled, Crossover Study Evaluating Aprepitant in Combination With a 5HT3 & Dexamethasone in Patients With Germ Cell Tumors Undergoing 5 Day Cisplatin-Based Chemotherapy Regimen
Status: Enrolling
Updated:  3/8/2016
Siteman Cancer Center
mi
from
St. Louis, MO
Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors
Phase III, Double-Blind, Placebo-Controlled, Crossover Study Evaluating Aprepitant in Combination With a 5HT3 & Dexamethasone in Patients With Germ Cell Tumors Undergoing 5 Day Cisplatin-Based Chemotherapy Regimen
Status: Enrolling
Updated: 3/8/2016
Siteman Cancer Center
mi
from
St. Louis, MO
Click here to add this to my saved trials